Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding EBIT Margin

The EBIT Margin (Operating Margin) of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 18, 2026 is 31.34 %. In the previous year, EBIT Margin (Operating Margin) was 41.35 % — a change of -24.20% (lower).

EBIT Margin

31.34 %

YoY

-24.20%

Last updated:

EBIT Margin (Operating Margin) of Tibet Rhodiola Pharmaceutical Holding is 2025 31.34 % . EBIT Margin (Operating Margin) of Tibet Rhodiola Pharmaceutical Holding was 2024 41.35 % . It decreases by -24.20% lower compared to the previous year.

Tibet Rhodiola Pharmaceutical Holding's operating (EBIT) margin stands at 31.3%, up from 12.0% several years earlier.

The Tibet Rhodiola Pharmaceutical Holding EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
23.74 CNY
Jan 1, 2019
27.96 CNY
Jan 1, 2020
34.38 CNY
Jan 1, 2021
12.01 CNY
Jan 1, 2022
18.19 CNY
Jan 1, 2023
28.69 CNY
Jan 1, 2024
41.35 CNY
Jan 1, 2025
31.34 CNY
The Tibet Rhodiola Pharmaceutical Holding EBIT Margin history
YEAREBIT MarginYoY
31.34 %-24.20%
41.35 %+44.13%
28.69 %+57.71%
18.19 %+51.47%
12.01 %-65.08%
34.38 %+22.96%
27.96 %+17.77%
23.74 %+1.84%
23.32 %-6.07%
24.82 %+221.84%
7.71 %+401.73%
1.54 %+24,791.73%
0.01 %-65.33%
0.02 %+222.64%
0.01 %-50.30%
0.01 %+61.39%
0.01 %-263.84%
-0.00-97.48%
-0.17 %+1,065.16%
-0.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co, listed on the Shanghai Stock Exchange under ticker 600211.SS, operates as a pharmaceutical company based in Lhasa, China. The company's ISIN is CNE000000ZW7. Founded through an IPO on July 21, 1999, it specializes in the manufacture and wholesale of pharmaceutical products. Its headquarters are located in Lhasa, Xizang, and it employs 615 full-time staff. The firm distributes proprietary drug products and processes pharmaceuticals, conducting business primarily across South China, North China, East China, Central China, and overseas markets. The company's website is http://www.xzyy.cn. It does not provide details on specific products, acquisitions, or financial figures beyond the IPO date and employee count. The company focuses on pharmaceutical manufacturing and distribution within its operational regions, with no additional information provided on its product lines or market share. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

EBIT Margin (Operating Margin) of Tibet Rhodiola Pharmaceutical Holding is 31.34 % in 2025.

EBIT Margin (Operating Margin) of Tibet Rhodiola Pharmaceutical Holding changed from 41.35 % to 31.34 %, representing a -24.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Tibet Rhodiola Pharmaceutical Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Tibet Rhodiola Pharmaceutical Holding

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding